Jingu Finance | Sino Biopharm (01177) announced that its subsidiary, Zentec Pharma, has signed an exclusive license and cooperation agreement with Uzuri Bio (02496), under which Zentec Pharma obtains the exclusive and separately licensable rights for the development, registration, production, and commercialization of M701 developed by Uzuri Bio in the mainland China region.
Depending on the progress of research and development, Zhen Dai Tian Qing will pay You Zhi You Biopharm an upfront payment and research and development milestone payment of approximately 0.315 billion yuan, and pay sales milestone payments of up to a maximum of 0.7 billion yuan, while also paying You Zhi You Biopharm a tiered royalty based on net annual sales percentages from single to double digits.
M701 is a new type of biopharmaceutical independently developed by Uzuri Bio, intended to be used for the treatment of malignant pleural effusion (MPE) and malignant ascites (MA) caused by tumors. It is currently in Phase III clinical trials, and is the first domestically developed CD3/EpCAM bispecific antibody to enter the clinical trial stage.
